Pipeline
Advancing a diverse clinical-stage pipeline of safe and highly effective tumour-targeted active immunotherapies to transform treatment across multiple cancer indications
Immunobody Iscib1+
SCIB1/iSCIB1+ Immunobody® Targeted DNA Active Immunotherapy for Advanced Melanoma
The Phase 2 SCOPE trial is an open label, multicohort, multicenter study in the UK evaluating SCIB1/iSCIB1+ in patients with advanced unresectable melanoma receiving either nivolumab with ipilimumab or pembrolizumab. To date, SCIB1/iSCIB1+ demonstrated compelling progression-free and overall survival with mature data expected in Q1 2027. Based on these results, the U.S. Food and Drug Administration has granted a iSBIC1+ a Fast Track Designation and cleared the IND for a Phase 3 trial of iSCIB1+ in patients with advanced melanoma with anticipated initiation in Q3 2026.
TUMOUR TARGETED
SCIB1/iSCIB1+ ImmunoBody® incorporates specific epitopes from the proteins gp100 and TRP-2, which play key roles in the production of melanin in the skin and were identified from T cells of patients who achieved spontaneous recovery from melanoma skin cancers. iSCIB1+ incorporates additional melanoma-specific epitopes in Class 1 HLA alleles, broadening the target patient population.
DUAL-ACTION
Direct and indirect Fc targeting via CD64 of activated dendritic cells initiates direct and cross-presentation of epitopes to T cells, resulting in higher T cell avidity of up to 100-fold increased potency and increased number of T cells to tumour epitopes.
Moditope Modi-1
Modi-1 Off-the-Shelf Neoantigen Peptide Active Immunotherapy Targeting Solid Tumours
The ModiFY study is an open-label, multicohort, multicentre, adaptive Phase 1/2 trial with Modi-1 being administered alone or in combination with checkpoint inhibitors in patients with advanced solid tumours. This open label Phase 1/2 study is assessing the safety and immunogenicity of citrullinated vimentin and enolase peptides.
Modi-1 completed dose escalation and safety cohorts of the Phase 1/2 ModiFY trial and continues in the expansion cohorts. Early data from patients receiving Modi-1 as a monotherapy showed good safety and tolerability, with no dose limiting toxicities observed in dose escalation cohorts. To build on the results in the ModiFY trial, we are investigating Modi-1 in renal cell carcinoma (RCC) in the first line setting where doublet CPI is the standard of care.
For commercial enquiries
Frequently Asked Questions
How do I join a trial?
Visit the Find a Trial page to locate a clinical site and contact us to find out how you can be included.
Are Scancell active immunotherapies personalised?
No, both Modi-1 and iSCIB1+ are off-the-shelf immunotherapies which means patients can access treatments fast and more cost effectively, instead of waiting for a personalised treatment which takes time to make.
I want to incorporate Scancell active immunotherapies into an existing clinical trial, how do I do this?
You can contact us using the Contact form
How is iSCIB1+ Immunobody® administered?
The iSCIB1+ immunotherapy) is given intramuscularly using the Pharmajet needle free injection system. Delivering SCIB1/iSCIB1+ intramuscularly via Stratis® has shown effective uptake of the DNA active immunotherapy and has the potential to provide clinical benefit to patients with advanced/metastatic melanoma by allowing native cellular machinery to express the target antigen and induce a potent anti-tumour response.
For more information read: Scancell signs strategic partnership with PharmaJet for use of the Stratis® IM Needle-free delivery System in the development of SCIB1/iSCIB1+ cancer vaccine for Advanced Melanoma – Scancell
Does Scancell have any Expanded Access Programs?
Currently Scancell does not have any expanded access programs for iSCIB1+ and / or Modi-1 open to patients that do not qualify for its ongoing clinical trials. This policy will be re-evaluated as additional safety and efficacy clinical data become available. Please do check back for updates.
Dr Heather Shaw, FRCP
Consultant Medical Oncologist
Mount Vernon Cancer Centre, Northwood, UK and University College London Hospital, London, UK
Dr Heather Shaw is a Consultant Medical Oncologist at Mount Vernon Cancer Centre in Northwood and lead for the Medical Oncology Skin Cancer Service at University College London Hospital, London. Dr Shaw’s main interests include the development of new strategies for the treatment of melanoma, including rare subtypes such as ocular, and novel therapies to overcome resistance to currently available treatments and maximise benefit for patients. She has a specialty interest in the management of immunotherapy adverse events and is involved in development of local and national guidance while leading services in both institutions for acute patient management.
Dr Shaw is the oncology representative on the Skin Cancer Prevention Group of the British Association of Dermatologists, a member of the national Uveal Melanoma Surveillance Guideline Committee, The Advanced Cellular Therapy Sub-Committee of British Society of Bone Marrow Transplantation and Cellular Therapy and has provided governmental advisory input to the UK All Party Parliamentary Group on Cancer with regard to cutaneous squamous cell carcinoma.
She is currently National Coordinating Investigator for a several international groundbreaking melanoma study including cellular and vaccine therapy indications which will deliver first in class licensed indications, and Principal Investigator for a large portfolio of melanoma, cutaneous squamous cell carcinoma, and early phase studies including first in human.
Prof. James Larkin
Consultant Medical Oncologist
Professor James Larkin is a Consultant Medical Oncologist in The Royal Marsden’s Skin and Urology units and is the Chief Clinical Investigator of translational studies into melanoma and kidney cancer.
Professor Larkin is Vice Chair of the Cancer Research UK Clinical Research Committee and Lead of the Uncommon Cancers theme at The Royal Marsden and ICR’s Biomedical Research Centre. In 2018, he was elected as a Fellow of the Academy of Medical Sciences. Since 2019, Professor Larkin has been Vice Chair of the Medical Oncology Specialist Advisory Committee for the Joint Royal Colleges of Physicians Training Board, and in 2020 was appointed as a Senior Investigator for the National Institute for Health Research.
He serves as a medical advisor to the patient advocacy group Melanoma UK, as a trustee of the Kidney Cancer Support Network and serves on the Medical Advisory Board of the International Kidney Cancer Coalition.
Dr Miranda Payne
Consultant in Medical Oncology
Dr Miranda Payne is a Consultant in Medical Oncology, specialising in the treatment of skin cancers, with expertise in the systemic treatment of melanoma. In 2006 Dr Payne was awarded a Cancer Research UK Clinical Fellowship, spending four years carrying laboratory research in DNA repair at the Weatherall Institute of Molecular Medicine, leading to a DPhil in Medical Oncology from the University of Oxford. Specialist training was completed in Oxford, where she is now the Clinical Lead for Oncology at the Oxford University Hospitals NHS Foundation Trust.
Recruitment to international, academic, industry-sponsored and observational clinical trials is a routine aspect of Dr Payne’s clinical practice within the NHS, reflected in her publication record. She has a special interest in the consequences of immunotherapy and in the management of mucosal melanoma. Miranda is the Thames Valley and South Midlands Skin Cancer Research Lead, is an elected member of the National Cancer Research Institute Skin Group, is a co-author of the recently published UK guidelines for the management of both Ano-uro-genital Mucosal Melanoma and Head & Neck Mucosal Melanoma, works with Melanoma Focus (the UK national charity dedicated to research, treatment, education and information for patients, their families and their clinical teams) and has been an editor of the Oxford Handbook of Oncology for over 15 years.
Prof. Poulam Patel, MBBS, FRCP, PhD
Professor of Clinical Oncology
Prof. Poulam Patel is the Professor of Clinical Oncology and Honorary Consultant Medical Oncologist at Nottingham University Hospitals NHS Trust. He is Chair of the EORTC Melanoma Study Group and currently serves as an advisor to a number of pharmaceutical companies and clinical-studies bodies. His research interests include the immunology of skin cancer (malignant melanoma), novel cancer vaccines, and immunotherapeutic approaches to malignancy. He has published over 60 papers covering basic research in tumor immunology and clinical trials in a range of tumors including first-in-man phase I trials. Prof . Patel is the UK co-ordinating Investigator for the SCOPE clinical trial.
Dr Pippa Corrie, PhD, FRCP
Consultant & Associate Lecturer in Medical Oncology
Dr Pippa Corrie PhD FRCP – Consultant and Associate Lecturer in Medical Oncology
Pippa Corrie established the Cambridge Cancer Trials Centre, led one of the first wave NCRN regional research networks and is now NIHR Clinical Research Network National Specialty Lead for Cancer: Late Phase and International Cancer Trials, as well as Cancer Specialty Lead for the NIHR Eastern Clinical Research Network.
Her specialist interests are in pancreaticobiliary cancers and melanoma. She chairs the NCRI Pancreatic Cancer Clinical Studies Subgroup and is Chief Investigator of several academic and commercial-sponsored NIHR portfolio pancreatic cancer and melanoma clinical trials.